search Search
search Search

Media Releases

    • myLoop to integrate Abbott’s future dual glucose-ketone sensor into their solution, combining YpsoPump and CamAPS FX, designed to improve the life of people living with diabetes.

    The planned integration will enhance the capabilities of myLoop by enabling people real-time access to both glucose and ketone data through a single wearable sensor. This enhanced functionality is designed to support more informed diabetes management, particularly for people with type 1 diabetes who are at risk of diabetic ketoacidosis (DKA), a serious complication caused by elevated ketone levels in the absence of sufficient insulin.

    myLoop combines the adaptive CamAPS FX app, the YpsoPump insulin pump and a continuous glucose monitoring (CGM) sensor to create an interoperable AID solution designed to simplify diabetes management.

    ‘‘By integrating Abbott’s future dual glucose-ketone sensor into myLoop, we aim to offer people with diabetes greater safety and confidence in their daily therapy’’

    said Sébastien Delarive, Chief Executive Officer at mylife Diabetes Care.

    ‘‘We are excited to collaborate with Abbott on this important innovation’’

    said Prof. Roman Hovorka, Director of CamDiab Ltd.

    ‘‘By incorporating future ketone monitoring alongside glucose data with the CamAPS FX app, we are taking a major step forward in delivering a closed-loop solution that is designed to enhance safety and reduces burden for people – and their loved ones living with type 1 diabetes.’’

    Subject to regulatory approval, the integrated solution is expected to become available in selected markets following the commercial release of Abbott’s dual glucose-ketone sensor, which is under development today.

    Go back